Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217


Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):463-5.


Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9.


Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.

Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM; Partners PrEP Study Team.

Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471.


Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.

Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM; Partners PrEP Study Team.

JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735.


Preexposure prophylaxis reduces HIV risk in injection-drug users.

Rosenberg K.

Am J Nurs. 2013 Sep;113(9):17. doi: 10.1097/01.NAJ.0000434163.23256.f7. No abstract available.


Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Myers GM, Mayer KH.

AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. Review.


Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.

Li J, Dufrene SL, Okulicz JF.

Ann Pharmacother. 2014 Apr;48(4):507-18. doi: 10.1177/1060028014520880. Epub 2014 Jan 28. Review.


Preexposure prophylaxis for the prevention of HIV transmission to women.

Aaron E, Cohan D.

AIDS. 2013 Jan 2;27(1):F1-5. doi: 10.1097/QAD.0b013e32835917b4.


Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S; Bangkok Tenofovir Study Group.

Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7. Epub 2013 Jun 13.


Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.

de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM.

Antimicrob Agents Chemother. 2011 Oct;55(10):4905-7. doi: 10.1128/AAC.00120-11. Epub 2011 Jul 25.


Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8.


Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.

Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S130-4. doi: 10.1097/QAI.0b013e3182986fac.


Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.

Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B, Hammer S; HVTN 505 Protocol Team.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):259-62. doi: 10.1097/QAI.0b013e318296df94.


No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.

PLoS One. 2013 Dec 18;8(12):e81997. doi: 10.1371/journal.pone.0081997. eCollection 2013.


Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Baeten JM, Haberer JE, Liu AY, Sista N.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S122-9. doi: 10.1097/QAI.0b013e3182986f69. Review.


Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.

Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA; Partners PrEP Study Team.

J Infect Dis. 2015 Apr 15;211(8):1211-8. doi: 10.1093/infdis/jiu677. Epub 2015 Jan 13.


Implications of HIV PrEP trials results.

Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D; Workshop Organizing Committee.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):81-90. doi: 10.1089/AID.2010.0226. Epub 2010 Dec 12.


HIV preexposure prophylaxis: new data and potential use.

Celum CL.

Top Antivir Med. 2011 Dec;19(5):181-5.


HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP.

Clin Infect Dis. 2009 Mar 15;48(6):806-15. doi: 10.1086/597095.

Supplemental Content

Support Center